GlassScriptPhysician profile
Mary Mitchell
NPI 1518481779
$1,602.85
in general payments reported to CMS, 2019-2025
17 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $323 · 2023: $344 · 2024: $587 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,255 · Education: $25.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,254.66 |
| Education | $25.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $488.68 | 2021-2025 | |
| Celgene Corporation | $264.32 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $193.43 | 2023-2025 | Stelara, Tremfya |
| Madrigal Pharmaceuticals | $104.90 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $83.39 | 2021-2025 | Entyvio, Eohilia |
| Celltrion USA INC. | $74.50 | 2024 | Vegzelma, Zymfentra |
| Aimmune Therapeutics, INC. | $73.96 | 2023-2025 | Vowst |
| E.R. Squibb & Sons, L.L.C. | $71.64 | 2021 | |
| Braintree Laboratories, INC. | $54.36 | 2024-2025 | Suflave, Sutab |
| Pfizer INC. | $33.50 | 2024-2025 | |
| Genzyme Corporation | $33.12 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.97 | 2023-2024 | |
| Medtronic, INC. | $24.64 | 2023 | Interstim |
| Vivus LLC | $20.31 | 2023 | Pancreaze |
| Exact Sciences Corporation | $17.97 | 2025 | Cologuard Collection Kit |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.98 | 2024 | |
| Janssen Scientific Affairs, LLC | $15.18 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.